Jasco Pharmaceuticals, LLC

Epix Pharmaceuticals, Inc.

Collagen Medical, LLC

Epix Medical, Inc.

Factor 1a, LLC

Stephane A Dumas

Andrew Kolodziej

Carmen M Baldino

Justin L Caserta

Chee-Seng Lee

Yvonne L Flanders

Peter Caravan

Zhaoda Zhang

Thomas J McMurry

Aaron Sato

Vincent Jacques

Richard J Looby

Robert B Nicewonger

John C Amedio, Jr

Aida Abujoub

Steffi K Koerner

Wei-Chuan Sun

Biplab Kumar Das

David R Buckler

Randall B Lauffer

John Amedio

Theodore R West

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1&#x3b3;1, CK1&#x3b3;2, CK1&#x3b3;3, CK2, Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1&#x3b3;1, CK1&#x3b3;2, CK1&#x3b3;3, CK2, Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway.

Aminopyrimidine kinase inhibitors

Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.

Methods for collagen imaging

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim-1, Pim-2, Pim-3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1&#x3b3;), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGF&#x3b2; pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway.

Methods of collagen imaging

Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

Peptide-based multimeric targeted contrast agents

The present invention relates to compounds and methods for synthesizing compounds wherein the compounds exhibit extended circulating half-life in the blood. The increase in circulating half-life is achieved by conjugating polypeptides to binding groups that exhibit high affinity for human serum albumin.

Polypeptide conjugates with extended circulating half-lives

Targeting multimeric imaging agents through multilocus binding

Growing community of inventors

Cambridge, MA, United States of America

Stephane A Dumas